Slide 1: Investor Presentation March 2025
INVESTOR PRESENTATION MARCH 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act o
Slide 3: Sight Sciences Mission Statement
Sight Sciences MISSION STATEMENT Develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing.
Slide 4: A Glimpse Ahead
A Glimpse Ahead Innovation leader in two large, growing, underserved markets Near-term catalyst expected in TearCare market access Strong balance sheet supports significant investments in R&D pipeline, clinical and commercial infrastructure Strong gross margin and disciplined operating expense spend
Slide 5: The Path to Early Intervention
The Path to Early Intervention A STRATEGIC ROADMAP TO TRANSFORM EYECARE GOAL ¹ Source: Market Scope 2024 Report and JAMA Ophthalmology Prevalence of Glaucoma Among US Adults in 2022 Oct 17, 2024 . ²Source: Market Scope’s Q1-2023 US Ophthalmologist Survey. ³Source: Market Scope 2023 Dry Eye Products
Slide 6: Glaucoma
ZS a Glaucoma —
Slide 7: Glaucoma
Glaucoma Leading cause of irreversible blindness (behind cataracts)1 Predominantly managed with daily eye drops (compliance often poor)2 Normal Mild Moderate Severe Large + Underserved Markets $6.0 billion addressable U.S. market3 >4 million U.S. patients diagnosed with Glaucoma1 ¹ Source: Market Sc
Slide 8: Primary Open-Angle Glaucoma (POAG)
Primary Open-Angle Glaucoma (POAG) The Conventional Outflow Pathway is an important focal point in treating POAG. POAG is similar to a clog in a kitchen sink: The eye’s natural drainage system is called the conventional outflow pathway. Blockage of this system prevents aqueous fluid from draining. W
Slide 9: Effective + Intuitive Intervention
Effective + Intuitive Intervention OUR FLAGSHIP TECHNOLOGY SURGICAL GLAUCOMA Offering a comprehensive intervention that drives leading clinical outcomes for Primary Open-Angle Glaucoma (POAG) ¹ Estimate based on units of OMNI (and predicates) shipped as of December 31, 2024 Comprehensive treatment o
Slide 10: OMNI Comprehensively Treats the Conventional Outflow Pathway
OMNI Comprehensively Treats the Conventional Outflow Pathway Minimally Invasive + Efficacious A comprehensive procedure enabled by the OMNI® Surgical System to help restore natural outflow in the eye with up to 360° treatment of all three areas of resistance* in the conventional outflow pathway * Tr
Slide 11: OMNI is Proven with Robust Clinical Evidence & Broad FDA Indication
OMNI is Proven with Robust Clinical Evidence & Broad FDA Indication OMNI is the most comprehensive implant-free Minimally Invasive Glaucoma Surgery (MIGS) technology, designed to effectively treat the full spectrum of primary open-angle glaucoma (POAG) OMNI is the only MIGS device with an FDA indica
Slide 12: Consistent Efficacy of OMNI in Combination Cataract and Standalone Trials
Consistent Efficacy of OMNI in Combination Cataract (CC) and Standalone (SA) Clinical Trials References: GEMINI (Clin Ophthalmol. 2022;16:1225–1234); ROMEO (J Cataract Refract Surg. 2021;47(7):907–915; Ophthalmol Glaucoma. 2021;4(2):173–81); TREY (Int Ophthalmol (2022)); ROMEO 2 Year (Clin Ophthalmo
Slide 13: OMNI Addresses All Six MIGS POAG Categories
OMNI Addresses All Six Minimally Invasive Glaucoma Surgery (MIGS) POAG Categories Allows surgeons to customize treatment ¹ Represents Company analysis of third-party estimates based on 2024 data MILD DISEASE (40%)1 MODERATE DISEASE (40%)1 ADVANCED DISEASE (20%)1 ~$2B opportunity1 ~$2B opportunity1 ~
Slide 14: Large and Unmet Clinical Need for Standalone MIGS
Large and Unmet Clinical Need for Standalone MIGS Combination Cataract Standalone | 14 | 14 <15% of POAG eyes1, >90% of MIGS procedures2 Established, growing market Benefits from inherent IOP-lowering effect of cataract surgery Share-taking driven by efficacy, fast recovery times and attractive safe
Slide 15: MIGS for the Pseudophakic Patient
MIGS for the Pseudophakic Patient The Glaucoma Patient Journey*
Slide 16: Standalone Market Development is Underway
Standalone Market Development is Underway Claims data indicate increasing standalone usage of codes associated with OMNI1 OMNI technology meets enhanced efficacy and safety needs for standalone procedures ROMEO ROMEO two-year extension TREY Sole purpose of OR visit – degree and consistency of effica
Slide 17: Surgical Glaucoma Pipeline
Surgical Glaucoma Pipeline Developing Comprehensive Best-in-Class Portfolio *This pipeline product is under development and is not commercially available. The Company may suspend or discontinue pipeline development projects at any time. CURRENT PRODUCTS IN THE PIPELINE Injection of Sustained Release
Slide 18: Dry Eye Disease
ZS a Dry Eye Disease ~
Slide 19: Dry Eye Disease
Dry Eye Disease Linked to screen time, age (postmenopausal women, men 50+), systemic medication use Predominantly managed with daily eye drops (compliance often poor)1 Normal Mild Moderate Severe Large + Underserved Markets ~$3.0 billion addressable U.S. market2 >13 million U.S. patients diagnosed w
Slide 20: Overview: Tears and Meibomian Gland Disease (MGD)
Overview: Tears and Meibomian Gland Disease (MGD) TEAR FILM ANATOMY MEIBOMIAN GLANDS Tears consist of three layers Outermost layer consists of oily substance called meibum Coats and protects inner layers Prevents premature evaporation Healthy meibomian glands release liquid meibum with each blink In
Slide 21: A new order of care
A new order of care Effective intervention shouldn’t wait, because atrophy is irreversible1-3 TearCare® targets the root cause of MGD: obstructed glands4 TearCare® has been proven clinically superior to Restasis/cyclosporine5 Efficacy has been demonstrated within 1 week, with the power to last up to
Slide 22: ~$3.0 Billion Core MGD Opportunity
~$3.0 Billion Core MGD Opportunity ¹ Market Scope 2024 Dry Eye Products Report. ² Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472-478. ³ Assuming one treatmen
Slide 23: Dry Eye Disease (DED): Large + Underserved Disease State
6.8 – 8.3 Dry Eye Disease (DED): Large + Underserved Disease State ¹ Market Scope 2024 Dry Eye Products Report and internal estimates. ² Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective stu
Slide 24: Targeted + Intuitive Intervention
Targeted + Intuitive Intervention OUR TECHNOLOGIES DRY EYE Offering a comprehensive therapy intervention that drives leading clinical outcomes for evaporative dry eye disease ¹ Estimate based on Dry Eye Treatment Lids shipped as of December 31, 2024. Comprehensive therapy to treat diseased meibomian
Slide 25: TearCare: Designed to Treat MGD
TearCare: Designed to Treat MGD TearCare is the only interventional, open-eye, dry eye technology designed to melt and comprehensively remove meibomian gland obstructions and restore gland functionality and healthy oil production. ¹ Gupta et al. Cornea 2022;41:417–426 Thin, wearable SmartLids® confo
Slide 26: SAHARA RCT
SAHARA RCT 6 MONTH PUBLICATION: CLINICAL OPHTHAMOLOGY DATE: DEC 2023 Randomized Controlled Trial comparing TearCare and Restasis®1 Superiority + Durability2 + Head-to-Head Study TearCare vs Restasis1 + Large Trial (N=345) + Randomized + Masked ¹Restasis is a trademark of Allergan™ an AbbVie company
Slide 27: SAHARA RCT: Results
SAHARA RCT: Results ¹ Endpoints for SAHARA include superiority over Restasis at six months in our primary objective endpoint, tear break-up time. Study designed for 24 months to assess duration of effectiveness. ² Restasis is a trademark of Allergan™ an AbbVie company 3 Ocular Surface Disease Index
Slide 28: TearCare Strategy: Targeted + Scalable Growth
TearCare Strategy: Targeted + Scalable Growth ¹ Estimated as of December 31, 2024 2 As of December 31, 2024 Actively Engaging in Pursuit of Equitable Market Access With the power of TearCare, we can: Improve the lives of U.S. MGD patients Scale commercial resources with market access wins Target ~9,
Slide 29: What's Next
ZS a What's Next was
Slide 30: Revenue and Gross Margin
Revenue and Gross Margin Historical financial results, including with respect to revenue and gross margin, may not be indicative of future financial results due to numerous risks and uncertainties, including those addressed in the "Risk Factors" section of the Company's filings with the U.S. Securit
Slide 31: Strategic Value Creation Initiatives Represent Sustainable Growth Drivers
Strategic Value Creation Initiatives Represent Sustainable Growth Drivers Expand OMNI Utilization TearCare Access + Expansion Re-engagement with accounts post LCD clarity with restrictions in multiple MIGS Certification of new OMNI surgeons Gain share in combination cataract segment Continue develop
Slide 32: Why Now?
Why Now? Innovation leader in two large, growing, underserved markets Near-term catalyst expected in TearCare market access Strong balance sheet supports significant investments in R&D pipeline, clinical and commercial infrastructure Strong gross margin and disciplined operating expense spend The tr
Slide 33: Thank you!
Thank you! If you have any questions, please contact investor.relations@sightsciences.com © Sight Sciences and/or certain of its affiliates, All rights reserved.